Welcome to our dedicated page for MedWellAI news (Ticker: MWAI), a resource for investors and traders seeking the latest updates and insights on MedWellAI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MedWellAI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MedWellAI's position in the market.
MedWell Ai (OTCQB: MWAI) has partnered with BrighterMD to develop TeleMD.Ai, a comprehensive B2B and B2C healthcare telemedicine platform targeting the $24.46 billion corporate wellness market. Set to launch in October 2025, the platform will offer unlimited access to healthcare providers and certified telehealth therapists through subscription-based plans.
TeleMD.Ai's key features include 24/7 nationwide access, primary care telemedicine, mental health services, AI-enhanced personalized healthcare assessments, bilingual services, and a FREE LifeVitals app for biometric monitoring. The platform will integrate with 70,000+ pharmacies offering prescription benefits with up to 80% savings and no-cost access to 125 commonly prescribed medications.
MedWell Ai (OTCQB: MWAI), formerly Integrated Ventures, has completed its corporate rebranding and transformation into an AI-driven healthcare ecosystem. The company announced several key developments including a new trading symbol, corporate website, and the launch of multiple business operations.
The company's operations now comprise three main subsidiaries: MedWell USA, LLC (B2B e-commerce portal for pharma products), TeleMD.Ai (telemedicine platform under development), and MedWell Facilities, LLC (real estate and AI software platform for wellness clinics). MedWell USA has secured revenue share distribution and master licensing agreements for its e-commerce platform, which features over 80 products.